跳至主要内容
临床试验/EUCTR2017-001803-57-Outside-EU/EEA
EUCTR2017-001803-57-Outside-EU/EEA进行中(未招募)1 期

A randomized, study in healthy subjects to determine the bioavailability of 200 mg LCZ696 mini-tablet compared to the 200 mg LCZ696 final market image tablet

ovartis Pharmaceuticals Corp0 个研究点目标入组 40 人开始时间: 2017年8月14日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Healthy male and female subjects of non-child bearing potential, age 18 to 55 years of age included, and in good health as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory tests at screening.
  • Other protocol-defined inclusion criteria may apply.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 40
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Use of investigational drugs within 30 days or 5 half-lives of enrollment, whichever is longer. History of symptomatic orthostatic hypotension or syncope or clinically significant ECG abnormalities.
  • Other protocol-defined exclusion criteria may apply.

研究者

发起方
ovartis Pharmaceuticals Corp

相似试验

Bioavailability study with LCZ696 | 临床试验